Evaluation of metformin in combination with rifampicin containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis (METRIF): study protocol for a randomised clinical trial

Chandrasekaran Padmapriyadarsini,1 Perumal K Bhavani,1 Mohan Natrajan,1 Chinnayan Ponnuraja,1 Hemanth Kumar,1 Sivaramakrishnan N Gomathy,1 Randeep Guleria,2 Shaheed M Jawahar,3 Manjula Singh,4 Tanjore Balganesh,3 Soumya Swaminathan4,5

ABSTRACT

Introduction Shorter duration of treatment for the management of drug-susceptible pulmonary tuberculosis (TB) would be a significant improvement in the care of patients suffering from the disease. Besides newer drugs and regimens, other modalities like host-directed therapy are also being suggested to reach this goal. This study’s objective is to assess the efficacy and safety of metformin-containing anti-TB treatment (ATT) regimen in comparison to the standard 6-month ATT regimen in the treatment of patients with newly diagnosed sputum smear-positive drug-sensitive pulmonary TB.

Methods and analysis We are conducting a multicentric, randomised open-label controlled clinical trial to achieve the study objective. The intervention group will receive isoniazid (H), rifampicin (R), ethambutol (E) and pyrazinamide (Z) along with 1000 mg of daily metformin (Met) for the first 2 months while the control group will receive only HRE. After 2 months, both the groups will receive HRE daily for 4 months. The primary endpoint is time to sputum culture conversion. Secondary endpoints will include time to detection of *Mycobacterium tuberculosis* in sputum, pharmacokinetics and pharmacogenomics of study drugs, drug–drug interactions, safety and tolerability of the various combinations and measurement of autophagy and immune responses in the study participants.

Ethics and dissemination The ethics committee of the participating institutes have approved the study. Results from this trial will contribute to evidence towards constructing a shorter, effective and safe regimen for patients with TB. The results will be shared widely with the National Programme managers, policymakers and stakeholders through open access publications, dissemination meetings, conference abstracts and policy briefs. This is expected to provide a new standard of care for drug-sensitive patients with pulmonary TB who will not only reduce the number of clinic visits and lost to follow-up of patients from treatment but also reduce the burden on the healthcare system.

Strengths and limitations of this study

- Study design, randomised controlled clinical trial, will add considerable power to the study results and conclusion by decreasing bias (selection bias and observer bias) and minimising confounding of unequal distribution.
- This study design of randomised controlled clinical trial with stratification will also control group allocation, enhancing similarity of baseline features including disease severity in the two study arms. This will help us in subgroup analysis improving usefulness for clinical practice.
- Due to the strict exclusion and inclusion criteria of the clinical trial, the results from the clinical trial may not be generalisable to all groups of patients with tuberculosis.
- Due to the multicentric nature of the study, the heterogeneity of data may be present.
- Relapse rates may not be known in this trial as the study duration is only for 6 months of treatment as per the study objective.

Trial registration number CTRI/2018/01/011176; Pre-results.

INTRODUCTION

Globally in 2016, there were an estimated 10.4 million new cases of tuberculosis (TB) with five countries, India, Indonesia, China, Philippines and Pakistan, accounting for 56% of the total cases.1 There were an estimated 1.3 million TB deaths in 2016 among HIV-negative people and an additional 374,000 deaths among people living with HIV.1 Though effective regimens are available for the treatment
of drug-sensitive TB with more than 95% cure, the long duration of such regimens has posed problems for TB treatment and control. This, along with drug toxicity, results in poor adherence to treatment resulting in the emergence of drug resistance.

All these have led to an urgent need for more efficient anti-TB drugs, regimens as well as for newer modalities of treating TB. Drugs targeting the TB bacilli can result in the emergence of drug tolerance and resistance, thereby worsening the overall treatment outcomes. Thus, there exists a need to consider alternate modalities such as enhancing the host immune system for a faster and complete elimination of the TB bacilli. An efficient and functional immune system is essential to restrain and curb the growth of TB bacilli in the host. Yet, the TB bacilli can still elude the host immune responses, infect the host cells and either multiply or maintain long-term latency in those cells. ‘Host-targeted’ adjunct therapeutic strategies not only augment protective host immune responses but also reduce the chance of development of microbial resistance.

One of the host cell innate antimicrobial arsenals includes the capacity to destroy intracellular pathogens using the phagosomal machinery or autophagy pathway. Intracellular pathogens are effectively controlled by autophagy that is regulated by adenosine monophosphate-activated protein kinase (AMPK). The Mycobacterium tuberculosis virulence results from perturbations in the autophagy network and AMPK signalling. The antidiabetic drug metformin (MET; 1, 1-dimethyl biguanide) is an AMPK modulator that inhibits the intracellular growth of M. tuberculosis, restricts disease immunopathology and enhances the efficacy of conventional anti-TB drug. Given these promising findings, we plan to test whether the existing approved antidiabetic drug, metformin added to the existing anti-TB regimen, with its defined effects on host cell functions could be repurposed for effective and faster treatment of TB as compared with the current standard of care anti-TB regimens.

The primary objective of this study—the METRIF study—is to study the antibacterial activity, in terms of time to sputum culture conversion of metformin-containing anti-TB treatment (ATT) regimen instituted during the initial 8 weeks of treatment in patients with newly diagnosed sputum smear-positive pulmonary TB. Secondary objectives of the study are:

i. To compare the time to detection (TTD) of M. tuberculosis in culture in the group receiving metformin-containing regimen with the control group receiving ATT alone

ii. To study the autophagy-enhancing effect and host immune responses in the two groups

iii. To examine the postdosing serum concentration of anti-TB drugs and metformin, their interactions and the impact of genomics on these parameters (pharmacokinetics (PK) and pharmacogenomics) and

iv. To evaluate the safety and tolerability of metformin by measuring the incidence of treatment-emergent adverse events.

METHODS AND ANALYSIS

Study design and oversight

METRIF is a multisite, randomised, open-labelled, parallel arm, controlled clinical trial comparing the time to sputum culture conversion among patients with pulmonary TB receiving ATT with metformin (experimental arm) compared with those receiving ATT alone (control arm). The study is randomising 316 participants to one of the two treatment arms in a 1:1 allocation. The study is sponsored by the India TB Research Consortium of the Indian Council of Medical Research and Open Source Pharma Foundation and implemented by the National Institute of Research in Tuberculosis (NIRT), together with other specialised institutes. The institutional ethics committee of NIRT has approved the study (NIRT-IEC ID: 2017030, dated 14 December 2017) and National AIDS Research Institute (NARI) (NARI EC/2018–10 dated 16 February 2018) and will begin enrollment tentatively by 15 June 2018.

Study setting

We will implement METRIF study at three sites in India - NIRT, Chennai and its satellite centres in Madurai and Vellore, All India Institute of Medical Sciences, New Delhi and NARI, Pune. These sites will recruit study participants from academic institutions/hospitals as well as community clinics.

Study patients and eligibility

Adult patients previously untreated and newly diagnosed with pulmonary TB with at least two sputum smear sample, collected on two different occasions, positive for acid-fast bacilli and susceptible to rifampicin detected by cartridge-based nucleic acid amplification test will be eligible for the study. Table 1 provides the detailed inclusion and exclusion criteria. Patients who meet these criteria at presentation and attending the identified study sites will be approached to participate in the study.

Study regimen and drug dosing

We will randomly assign eligible patients who have provided written informed consent to one of the study regimens in a ratio of 1:1. The site principal investigator or his/her nominee who is capable of answering all the trial-related questions from the participants will obtain the study consent. Study participation will last 6 months: during the first 2 months, participants will receive the randomly assigned regimen of either daily ATT with metformin or only ATT.

(1) Test regimen – metformin+isoniazid+rifampicin+pyrazinamide+ethambutol daily [2MethREZ,] or

(2) Control regimen – isoniazid+rifampicin+pyrazinamide+ethambutol daily [2HRZE,]
After 2 months, all study participants in both the arms will receive the standard 4-month continuation phase of HRE daily. Treatment will be supervised and directly observed at a health facility or by directly observed therapy (DOT) provider. Metformin will be dosed at 500 mg once daily for the 1st week and then 1000 mg once daily for the remaining period of 7 weeks. Dosing of the other anti-TB drugs will be based on weight bands as shown in table 2.

We will centrally procure all drugs (H, R, E, Z and Met) to be used in the trial, check for their stated content by validated methods using high-performance liquid chromatography at NIRT clinical pharmacology department, before dispatching it to the enrolling sites for administration to patients.

**Treatment allocation**

Permuted block randomisation will be done centrally using a computer-generated list of random numbers, stratified by presence or absence of cavities in chest X-ray and highest sputum smear grading at baseline (<2 or >2). Separate randomisation lists for each combination of strata for each site will be prepared in advance by an independent statistician, using varying block sizes. Allocation codes will be generated at the central location and at the time of patient’s admission to the study; the primary statistician through email will inform the site the regimen based on appropriate stratification factors.

**Recruitment process**

We will screen all patients with newly diagnosed sputum smear-positive pulmonary TB attending the chest clinics at the study sites for study eligibility. Table 3 details the various study procedures. At their first visit, the study will be explained, including the potential risks and benefits associated with participation. We will obtain informed written consent before any protocol-specific screening procedures are carried out. Consenting participants will undergo sputum testing for smear, culture (both solid and liquid media) and rifampicin resistance testing by GeneXpert. Blood samples will be obtained for HIV antibodies (unless the patient is already known to be HIV positive), liver and renal function tests and blood sugar levels. Patients will be reassessed for eligibility when returning with their investigation results. Those patients who do not have rifampicin resistance and are willing to take part in the study will sign an enrolment consent form (or a thumb print in the presence of a witness, if illiterate), and randomised to one of the study regimens. During the first 2 months of treatment, all patients will undergo weekly sputum testing for M. tuberculosis by smear, liquid and solid cultures and sparse pharmacokinetics of ATT drugs and metformin. A subset of patients will undergo intense pharmacokinetic study. Randomised patients have an additional blood investigation for immunological and autophagy biomarkers (T cell, monocyte and dendritic cell functions both ex vivo and following stimulation with TB antigens including Purified Protein Derivative (PPD) and early secretory antigenic target, ESAT-6/CFP-10, Culture filtrate Protein, estimation of C reactive protein, tumour necrosis factor-α and other cytokines) pre and post metformin containing ATT.

---

**Table 1** Eligibility criteria

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age 18 years and above</td>
<td>Is pregnant or breastfeeding</td>
</tr>
<tr>
<td>Is willing to undergo HIV testing</td>
<td>Has extrapulmonary TB or drug-resistant TB</td>
</tr>
<tr>
<td>Has body weight between 30 kg and 65 kg</td>
<td>Has body weight &lt;30 kg or &gt;65 kg</td>
</tr>
<tr>
<td>Patient has never received treatment with multidrug anti-TB therapy for more than a week.</td>
<td>Has a prior history of exposure to anti-TB treatment for more than a week</td>
</tr>
<tr>
<td>Is willing to use an effective contraceptive method during the study period</td>
<td>Has a history of liver disease or current amino alanine transferase greater than three times the upper limit of normal (ULN) or total bilirubin concentration greater than 2.5 times the ULN</td>
</tr>
<tr>
<td>Is willing to attend a treatment centre for supervised treatment and remain within the study area limit</td>
<td>Is serology positive for hepatitis B virus surface antigen or hepatitis C virus antibody</td>
</tr>
<tr>
<td>Is willing to sign the informed consent form and adhere to trial procedures and follow-up</td>
<td>Has concomitant psychiatric illness or seizures</td>
</tr>
<tr>
<td>Consents for home visits by the study team</td>
<td>Has concomitant diabetes mellitus or random blood sugar &gt;200 mg or fasting blood sugar &gt;140 mg/dL</td>
</tr>
<tr>
<td></td>
<td>Has serum creatinine &gt;1.2 mg/dL or blood urea &gt;43 mg/dL</td>
</tr>
</tbody>
</table>

**Table 2** Weight-based dosing of anti-tuberculosis drugs

<table>
<thead>
<tr>
<th>Weight band</th>
<th>Isoniazid</th>
<th>Rifampicin</th>
<th>Pyrazinamide</th>
<th>Ethambutol</th>
</tr>
</thead>
<tbody>
<tr>
<td>30–39 kg</td>
<td>150 mg</td>
<td>300 mg</td>
<td>800 mg</td>
<td>550 mg</td>
</tr>
<tr>
<td>40–54 kg</td>
<td>225 mg</td>
<td>450 mg</td>
<td>1200 mg</td>
<td>825 mg</td>
</tr>
<tr>
<td>55–65 kg</td>
<td>300 mg</td>
<td>600 mg</td>
<td>1600 mg</td>
<td>1100 mg</td>
</tr>
</tbody>
</table>
Table 3  Study schedule of enrolment, interventions and assessments.

<table>
<thead>
<tr>
<th>Study period</th>
<th>Intensive phase of ATT (Trial period)</th>
<th>Continuation phase of ATT (Post-trial period)</th>
<th>Closeout</th>
</tr>
</thead>
<tbody>
<tr>
<td>I Enrolment</td>
<td>Baseline (-D7) 0 W 1 W 2 W 3 W 4 W 5 W 6 W 7 W 8 M 3 M 4 M 5 M 6 M 7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Informed consent</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Eligibility screen (including laboratory tests)</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Sputum Gene Xpert</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 HIV, hepatitis B and C</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II Allocation</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III Trial regimens</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test regimen (metformin containing ATT)</td>
<td>x</td>
<td>x x x x x x x x</td>
<td></td>
</tr>
<tr>
<td>Control regimen (only ATT)</td>
<td>x</td>
<td>x x x x x x x x</td>
<td>x x x x</td>
</tr>
<tr>
<td>Continuation phase of ATT (for both groups)</td>
<td></td>
<td></td>
<td>x x x x</td>
</tr>
<tr>
<td>IV Assessments</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Clinical evaluation</td>
<td>x</td>
<td>x x x x x x x x x x x x x x</td>
<td>x x x x</td>
</tr>
<tr>
<td>2 Sociological assessment</td>
<td>x</td>
<td>x</td>
<td>x x x x x x x x</td>
</tr>
<tr>
<td>3 Sputum smear and culture (MGIT, LJ)</td>
<td>x</td>
<td>x x x x x x x x x x x x</td>
<td>x x x x</td>
</tr>
<tr>
<td>4 Urine pregnancy tests/sugar/Alb</td>
<td>x</td>
<td>x</td>
<td>x x x x x x</td>
</tr>
<tr>
<td>5 HbA1c</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>6 CBC, LFT, RFT, lactic acid, peripheral smear and chest X-ray</td>
<td>x</td>
<td></td>
<td>x x</td>
</tr>
<tr>
<td>7 Random blood sugar</td>
<td>x</td>
<td></td>
<td>x x x</td>
</tr>
<tr>
<td>8 Pharmacokinetics and genomics</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>9 Immunological studies</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>10 Storage plasma/cell sample</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>V Outcomes</td>
<td></td>
<td></td>
<td>x</td>
</tr>
</tbody>
</table>
We will refer patients ineligible or unwilling to participate in the study to the national programme for treatment as per the existing guidelines.

**Treatment delivery, compliance and retention**

ATT will be administered under direct observation for 6 days of the week and supplied for the 7th day. Study staff will reinforce the importance of adherence to the treatment schedule at each visit. If the patient misses drug doses in the intensive phase (IP) or continuation phase (CP), it will be compensated at the end of the respective stages over next 15 days, so that the patient receives 60 doses of the assigned regimen in the IP and 120 doses in the CP. Treatment supporters and enablers will facilitate retention of the participants in the study. All treatment is ambulatory and delivered by dedicated DOT provider. We will assess treatment adherence through reviews of treatment card throughout the treatment phase. In case of drug supply for any reason, empty pill cover count will determine adherence. Treatment adherence will be enhanced by reimbursing the transport costs and loss of wages incurred by the participant during the study visits. During the study period, participants will receive food supplement every month and meals during their extended study visits.

**Concomitant medication while in the trial**

Concomitant antibiotic treatments of any kind are discouraged during the study period. If required, their usage is restricted for a short course (<2 weeks) period. Concomitant non-antibiotic drug usage is allowed in small quantity. Only those considered necessary for the subject’s welfare and are unlikely to interfere with the study medication may be given at the discretion of the investigator. Below are the drugs used to treat *M. tuberculosis* infections which should not be used during this trial: streptomycin, thiacetazone, PAS, dapson, amoxicillin-clavulanic acid/clavulanate, clofazimine, capreomycin, any oxazolidinone antibiotic (eg, linezolid), ofloxacin, levofloxacin or moxifloxacin.

**Criteria for discontinuation/withdrawal of study participants**

Withdrawal of study participants can occur for any of the following reasons: pregnancy, if the investigators feel that staying in the study is harmful to the patient, if the patient does not follow study procedures or is not available for appointments, if the study sponsor or NIRT or representative of the Drugs Controller General of India decides to stop or cancel the study, if the Data and Safety Monitoring Board recommends halting the study or if the patient wishes to withdraw for any reasons. In such cases, appropriate treatment as per the standard of care treatment available then will be ensured for patients taking into consideration the drug susceptibility pattern of the individual.

**Study outcomes**

The primary outcome is the time to sputum culture conversion, which is assessed by the time interval between the date of treatment initiation and the date of acquisition of the first of at least two consecutive negative cultures taken at least 8 days apart. We will also assess, on a weekly basis, the time to positivity, a change in *M. tuberculosis* log10 colony forming units (CFU) in culture and the proportion of participants with sputum culture negativity in the two treatment arms.

The PK, the area under the concentration curve (AUC), will be assessed through blood sampling on a single day during the first month of ATT, after a minimum of seven doses of RMP and MET (1000 mg). We will estimate the minimum inhibitory concentration (MIC) of each participant’s pretreatment infecting isolate from early morning and overnight sputum samples collected at the pretreatment visit. We will also compare the genomics results of metformin and rifampicin with the plasma concentration of these drugs, bacteriological and clinical endpoints along with the drug–drug interaction of metformin and rifampicin.

For the occurrence of treatment-emergent adverse events (TEAEs), clinical investigators will grade clinical and laboratory abnormalities according to the modified Adult Toxicity Table for the Division of Microbiology and Infectious Diseases, National Institutes of Health. The safety and tolerability analysis will include all patients who were randomised to and received at least one dose of the study regimen.

**Participant timeline**

The trial will consist of three stages: screening and enrolment (a maximum of 1 week); the intensive phase of treatment with or without test drug (2 months) followed by a continuation phase of standard drugs (4 months). Table 3 shows the schedule of enrolment, interventions and assessments of participants in the trial.

**Patient and public involvement**

Patients were not involved in the development of the research question or the design of this study as the scientific problem is still not proven and only in the research arena. However, considering the relevance of the study outcome to public health and policy-makers, the study is discussed in our Institutional Scientific advisory committee, Institutional Ethics committee and Community Advisory Board consisting of a representative from affected community, peers and responsible members of the society. Patients will be involved in the recruitment and conduct of the study. We will disseminate the results of the study widely through meetings, workshops, conference presentation and publication.

**Sample size assumption**

Published literature has shown a median time to sputum culture conversion by a liquid medium with daily ATT to be 32 days. With the addition of metformin, we assumed a 30% reduction in the time to culture conversion, that is, to approximately 22 days. We estimated that we would require 150 new sputum smear-positive patients to show...
this difference at 80% power, an alpha level of 0.05 and
an HR of 1.5. With the assumption that 5% of patients
will be lost to follow-up or not assessable in the primary
analysis, a total target sample size of 158 patients in each
treatment arm will be recruited, totalling to 316 patients
for the study.

Randomisation procedures
Permuted block randomization will be done centrally
using a computer-generated list of random numbers,
stratified by presence or absence of cavities on chest
X-ray and highest sputum smear grading (<2 or >2). The
randomisation sequence will not be available to those
who enrol participants. Allocation codes will be gener-
ated at the central site, NIRT, and will take place at the
time of patient’s admission to the study. On receiving an
email mail request from the study sites, for allocation
of a participant to the study, the NIRT statistician will do
allocation procedure centrally based on appropriate strat-
ification factors. He/She will then inform the site physi-
cian, through e-mail, the study regimen along with the
unique study ID for patient enrolment to the study.

Data collection, management and interim analysis
Study randomisation will be done centrally by the Central
Data management (CDM) unit at NIRT, Chennai over
email. During the study conduct, data will be collected at
sites at baseline and follow-up on predefined case record
forms (CRF) and transmitted electronically to the CDM
unit. Data correctness and completeness will be checked
before sending. The central team will also conduct a peri-
dic quality check of the data. Data collected will include
(1) improvement in disease status regarding abatement of
symptoms, signs and sputum cultures conversion and (2)
safety and tolerability of the regimen concerning both
clinical and laboratory adverse events (AEs).

During the trial, all essential trial documents including
the source documents, informed consent forms, etc will
be stored securely under lock and key at the recruiting
sites under the supervision of the site investigator. All
e-data will be password protected with limited access to
the investigator and their teams alone. The study team
will retain the records for a minimum period of 5years
after completion of the study.

The study has two interim analyses planned, viz. after
33% and 66% of the enrolled patients have completed
8weeks of metformin treatment and with sputum culture
results available for review. The study also has an addi-
tional interim analysis for reported serious adverse events
(SAEs) with frequency higher than anticipated. The final
analysis will include all enrolled patients when they have completed 6months of ATT.

Study outcome analysis
The primary efficacy analysis will compare the median
time to culture negativity. This analysis will happen when
the last enrolled patient has completed 8 weeks of treat-
ment and will be done using culture results from liquid
culture (MGIT) and in those who are not isoniazid or
RMP mono-resistant at baseline. Both a modified intent
to treat (MITT) and a per protocol (PP) analysis will be
conducted. Secondary outcome parameters will include
proportion and time to sputum culture positivity using the
MGIT system. The safety and tolerability analysis
will consist of all patients who were randomised to and
received at least one dose of the drug. Based on plasma
drug concentrations obtained at different time points, we
will calculate certain pharmacokinetic variables related to
study drugs. Drug peak concentrations (Cmax) and expo-
sure (AUC) will be linked to time to sputum conversion
and occurrence of AEs.

Data and Safety Monitoring Board
The Data and Safety Monitoring Board (DSMB) for this
study comprises TB clinicians, pharmacokinetic special-
ist and an independent biostatistician. They will review
data from this trial on a regular basis, including incidence
progress of the trial, and detect evidence of early safety
issues for the trial participants with a specific focus on
grade 3 or 4 AEs, SAEs and treatment discontinuations
due to AE. Based on the results, DSMB shall make recom-
mendations on continuing or terminating/modifica-
tions to the trial.

Clinical site monitoring and quality assurance
An independent study monitor, appointed by the sponsor,
will be responsible for monitoring data quality by trial
standard operating procedures. Based on the monitoring
plan, field visit and audit will be performed at different
stages. All participant records, CRFs and other source
documents for the patients recruited in this study will be
made available for review by the monitors. A meeting of
the investigators of each local site will convene monthly
via web-based remote conference system to share the
progress of the study and discuss with the problems
met during the trial conduct. During the conduct of
the research, any critical protocol modifications will be
informed to the IEC, trial registry and, if relevant, to the
trial participants.

Confidentiality of trial data
The processing of personal data in this trial will be limited
to those data that are reasonably necessary to investigate
the antibacterial activity, safety and tolerability of the
investigational product used in this trial. These data will
be processed with adequate precautions to ensure confi-
dentiality. Trained professional will collect all study data
with the utmost sensitivity and confidentiality. The study
participant will be informed during the informed consent
process that: the monitor(s) the IEC, and the regulatory
authorities will be granted direct access to the partici-
 pant’s original medical records for verification of clinical
trial procedures and/or data, without violating the confi-
dentiality of the participant, to the extent permitted by
the applicable laws. Otherwise, only the study investigator
and his/her team will have access to the trial data.


Open access
ETHICS AND DISSEMINATION

This trial will proceed as per the current ICH Good Clinical Practice and the ICMR ethical guidelines for biomedical research in human participants. Compliance with this standard provides public assurance that the rights, safety and well-being of trial subjects are protected, consistent with the principles that have their origin in the Declaration of Helsinki, and that the clinical trial data are credible. The confidentiality of the study participants will be protected throughout the study period as per provision in the Indian-GCP and applicable regulations by laws of India. The processing of personal data in this trial will be limited to those data that are reasonably necessary to investigate the antibacterial activity, safety and tolerability of the investigational product used in this trial.

The study principal investigator holds primary responsibility for the preparation of manuscripts and materials for result dissemination and publication. Once the trial is complete, the investigators anticipate publishing results of this study in several peer-reviewed scientific journals, present the abstracts in meetings, to stakeholders and policymakers and share the results widely with the programme managers. During all these processes, details of the trial participant will remain confidential.

DISCUSSION

Currently, for the management of patients with newly diagnosed sputum smear-positive drug-sensitive pulmonary TB, 6-month regimens are used in more than 90 countries that are evaluated to be effective. Newer anti-TB drugs are also in the pipeline. However, all types of treatment currently available are pathogen-targeted and with toxic drugs. Drug toxicity can lead to poor treatment adherence resulting in treatment failure and development of resistance. As the pathogen-targeted strategies may lead to the development of acquired microbial resistance, new ‘host-targeted’ adjunct therapeutic approaches not only are less likely to engender microbial resistance but also augment protective host immune responses, thus accelerating bacterial clearance from the system.

Metformin has an inhibitory effect on mitochondrial complex I, inhibition of which has been found to increase the AMP/ATP ratio. The altered cellular energy status induces activation of AMPK, a serine/threonine kinase, and acts as an energy sensor. Activation of AMPK by metformin stimulates endothelial nitric oxide synthase activity which leads to bacterial killing. Metformin also acts through AMPK-independent mechanisms. It promotes phagocytosis, phagolysosome fusion and autophagy in macrophages. Macrophages exposed to metformin had higher bactericidal capacity attributed to increased mitochondrial reactive oxidative species (ROS) production required for bacterial killing. Approximately 90% of the newly diagnosed sputum-positive patients are sensitive to isoniazid (H) and rifampicin (R), adding the drug metformin would have a beneficial effect in the early killing of intracellular bacteria by influencing the host immunity. Experiments in mice treated with MET (200 mg/kg) along with H 10 mg/kg showed not only a considerable reduction in the bacillary load in the lungs but also reduced areas of lung tissue damage compared with H-alone treatment. This dose of MET is equivalent to approximately 1200 mg/day for a 60 kg human and this dose of MET will be used in this trial along with H, R, E and Z in the intensive phase of daily ATT. High dose of metformin has also been used in clinical practice for the management of diabetic individuals with and without TB and in non-diabetic conditions like polycystic ovarian syndrome and obesity. Though WHO recommends 2HRZE/4-hour regimen for new patients with pulmonary TB, given the high prevalence of isoniazid resistance in the country (11% in new sputum-positive patients), the Revised National TB control programme of India recommends using three drugs in the continuation phase, that is, 2HRZE+/4HRE regimen which will be followed in this trial.

We are proposing a phase IIB trial looking at sputum-culture conversion to negative over a 2-month period as studies have shown a correlation between positive 2-month sputum culture status and subsequent relapse. However, limitations of this design include the binary outcome of 2-month sputum culture endpoint, hence requiring larger samples size to prove the benefit. To overcome this limitation, we plan serial sputum colony counting (SSCC) and time-to-detection (TTD). SSCC involves counting of viable M. tuberculosis bacilli at various time points during the 8-week period. This measurement will demonstrate the rapid bacillary killing in the early phase and track the rate and pattern of culture conversion throughout the 8 weeks, thereby providing a better marker for culture conversion. However, TTD in liquid culture is considered an even better choice than SSCC as the complications of counting viable colonies is replaced by automated measurement of detection time of the bacilli throughout the 8-week period. In our study, as the outcome measures of interest (primarily bacteriological) are based on objective microbiology, the bacteriology laboratory staff will be blinded to the patient’s treatment. Safety assessments will be defined as objectively as possible, using predefined grading criteria for laboratory abnormalities and AEs. The pharmacokinetic aspect of the study is based on a population approach which is facilitated by the intensive-sparse sampling design. The study will estimate the pharmacokinetic exposure (AUC0–24) for all study participants. Several alternative biomarkers of treatment response are also being evaluated using these samples.

Results from METrif study will complement observations from other retrospective and case–control studies that showed metformin to be a protective agent against TB infection among people with diabetes. As studies did not show any dose-dependent protection in metformin users for TB, we will be using 500 mg dose for the first week followed by 1000 mg for the remaining 7 weeks. This dose escalation is being done to reduce the gastrointestinal side
effects of metformin. If the study regimen is successful, it will pave the way to evaluate shorter regimens for the treatment of pulmonary TB. This trial will establish a new standard of care for DS-pulmonary TB that will not only reduce the number of required clinic visits by the patients but also decrease the proportion of patients who fail to complete the full course of therapy. It should also reduce the overall burden on the healthcare system. If the study regimens are shown to be superior or at least non-inferior to the control regimen, then the procedure represents an even greater advantage for both patients and TB control programmes throughout the world.

Author affiliations
1ICMR-National Institute for Research in Tuberculosis, Chennai, India
2All India Institute of Medical Sciences, New Delhi, India
3Open Source Pharma Foundation, Chennai, India
4Indian Council of Medical Research-India TB Research Consortium, New Delhi, India
5World Health Organisation, Geneva, Switzerland

Contributors CP and SS: conceived and designed the study. CP, PKB, MN, CPR, HK, NSG, RG, SJ, TB, SS: development and writing of the study protocol and this manuscript.

Funding India TB Research Consortium, Indian Council of Medical Research, New Delhi and Open Source Pharma Foundation, Bangalore, India provided funding for the study. Trial Sponsor: Indian Council of Medical Research – National Institute for Research in Tuberculosis.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES